Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

Salim Surani, Pahnwat T. Taweesedt, Sara Surani, Iqbal Ratnani, Joseph Varon

Research output: Contribution to journalArticlepeer-review

Abstract

The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.

Original languageEnglish (US)
Article numbere187430642202040
JournalOpen Respiratory Medicine Journal
Volume16
Issue number1
DOIs
StatePublished - 2022

Keywords

  • Cerebral venous embolism
  • COVID-19
  • Delta variant
  • mRNA Vaccines
  • Myocarditis
  • SARS-CoV-2
  • Vaccines

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One'. Together they form a unique fingerprint.

Cite this